Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
1. Unusual Suspects in the Twilight Zone between the Hsp90 Interactome and Carcinogenesis
Evangelia Vartholomaiou, Pablo C. Echeverría and Didier Picard
2. Impact of Post-translational Modifications on the Anticancer Activity of Hsp90 Inhibitors
Mark R. Woodford, Diana Dunn, Jonelle B. Miller,Sami Jamal, Len Neckers and Mehdi Mollapour
3. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects
Gaurav Garg, Anuj Khandelwal and Brian S. J. Blagg
4. HSP90 in Cancer: Transcriptional Roles in the Nucleus
S. K. Calderwood and L. Neckers
5. Hsp90 as a ‘Chaperone’ of the Epigenome: Insights and Opportunities for Cancer Therapy
Jennifer S. Isaacs
6. Emerging Roles of Extracellular Hsp90 in Cancer
Daniel Senh Wong and Daniel G. Jay
7. GRP94/gp96 in Cancer: Biology, Structure, Immunology and Drug Development
Bill X Wu, Feng Hong, Yongliang Zhang, Ephraim Ansa-Addo and Zihai Li
8. HSP90 and Immune Modulation in Cancer
Michael W. Graner
9. Hsp90: A Global Regulator of the Genotype-To-Phenotype Map in Cancers
Hsp90 in Cancer: Beyond the Usual Suspects, the latest volume in the Advances in Cancer Research series, focuses on the multifunctional molecular chaperone Hsp90 which regulates the post-translational stability and function of a broad repertoire of client proteins and discusses some of the lesser-known aspects of how Hsp90 and its related family members enable oncogenic transformation and malignant progression.
- Focuses on the multifunctional molecular chaperone Hsp90 which regulates the post-translational stability and function of a broad repertoire of client proteins
- Highlights the rapidly evolving understanding of the fundamental roles of Hsp90 in cancer biology
- Discusses the lesser-known aspects of how Hsp90 and its related family members enable oncogenic transformation and malignant progression
The information in this volume will be of interest to a broad range of basic and translational scientists, not only in the relatively narrow field of protein folding/biochemistry, but in other areas of cancer biology and clinical oncology.
- No. of pages:
- © Academic Press 2016
- 22nd February 2016
- Academic Press
- Hardcover ISBN:
- eBook ISBN:
Praise for the Serial
"This classic and essential series presents critical overviews on select aspects of both cancer
research and the basic underlying sciences." --American Scientist
"Excellent, highly informative, in-depth reviews…expertly written, up-to-date, and
well-referenced." --Journal of Medicinal Chemistry
"This is a series that has a long tradition of excellence in the field of cancer biology." --Doody’s Publishing Reviews
Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA
Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, USA
Luke Whitesell is a pediatric oncologist and senior research scientist at the Whitehead Institute. His clinical interests lie in the treatment of children with recurrent, refractory solid tumors. His laboratory efforts focus on the discovery and pre-clinical development of new anticancer drugs that target heat-shock proteins and the cellular heat-shock response. These ancient adaptive mechanisms act genome-wide to restore the normal protein folding environment within cells and enhance the survival of organisms under stress. In contrast to such well-recognized beneficial effects, however, they also enable cells to accommodate the drastic imbalances in signaling and profound alterations in DNA, protein and energy metabolism that occur in cancers. In essence, the malignant lifestyle confers a profound dependence on these “non-oncogenes”, strongly supporting the feasibility of targeting them to more effectively treat cancers. Building on these basic insights and the surprising ways in which HSP90 supports the evolution of new abilities in model organisms, a major goal of his current work is to test the idea that inhibiting HSP90 function can delay or prevent the evolution of a very undesirable trait in cancers, namely the acquisition of high level resistance to current chemotherapies.
Luke pursued graduate work in pharmacology at Cambridge University prior to completing medical training at Johns Hopkins University and residency at Boston Children’s Hospital. After fellowship training at the National Cancer Institute he joined the University of Arizona where he was Professor of Pediatric Oncology in the College of Medicine prior to taking his current position at the Whitehead Institute in Cambridge, MA.
Whitehead Institute for Biomedical Research, Cambridge, USA